文献速递白血病

WT1与RUNX1::RUNX1T1协同靶向DUSP6以抑制急性髓系白血病中的ERK活性

WT1 together with RUNX1::RUNX1T1 targets DUSP6 to dampen ERK activity in acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2024-08-27

本研究验证了WT1表达在急性髓系白血病(AML)中的预后意义,并利用转染细胞系和异种移植瘤模型发现,WT1在RUNX1::RUNX1T1阳性AML中抑制增殖并增强阿糖胞苷效应,而在无RUNX1::RUNX1T1的AML细胞中功能相反;机制上WT1与RUNX1::RUNX1T1物理互作并作为辅因子激活DUSP6表达以抑制ERK活性。

要点

  • WT1在RUNX1::RUNX1T1阳性AML中抑制增殖并增强阿糖胞苷效应,在无RUNX1::RUNX1T1的AML细胞中功能相反。
  • WT1与RUNX1::RUNX1T1物理互作,作为辅因子共同激活DUSP6表达以抑制ERK活性。
  • RUNX1::RUNX1T1缺失时,WT1可激活MEK/ERK轴但不通过靶向DUSP6。

核心结论

  • WT1与RUNX1::RUNX1T1协同通过WT1/DUSP6/ERK轴抑制AML细胞增殖,为WT1表达在AML中相互矛盾的预后意义提供了解释。

研究设计与样本

  • 研究首先在临床队列中验证WT1表达的预后意义,随后使用已建立的转染细胞系和异种移植瘤模型进行机制研究。

主要发现

  • 在RUNX1::RUNX1T1阳性AML中,WT1抑制增殖并增强阿糖胞苷效应;在无RUNX1::RUNX1T1的AML细胞中功能相反。
  • WT1作为转录因子与RUNX1::RUNX1T1物理互作,作为辅因子共同激活靶基因DUSP6表达以抑制ERK活性。
  • RUNX1::RUNX1T1缺失时,WT1可激活MEK/ERK轴但不通过靶向DUSP6。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Wilms' tumour 1 (WT1) can function as an oncogene or a tumour suppressor. Our previous clinical cohort studies showed that low WT1 expression at diagnosis independently predicted poor outcomes in acute myeloid leukaemia (AML) with RUNX1::RUNX1T1, whereas it had an opposite role in AML with non-favourable cytogenetic risk (RUNX1::RUNX1T1-deficient). The molecular mechanism by which RUNX1::RUNX1T1 affects the prognostic significance of WT1 in AML remains unknown. In the present study, first we validated the prognostic significance of WT1 expression in AML. Then by using the established transfected cell lines and xenograft tumour model, we found that WT1 suppresses proliferation and enhances effect of cytarabine in RUNX1::RUNX1T1(+) AML but has opposite functions in AML cells without RUNX1::RUNX1T1. Furthermore, as a transcription factor, WT1 physically interacts with RUNX1::RUNX1T1 and acts as a co-factor together with RUNX1::RUNX1T1 to activate the expression of its target gene DUSP6 to dampen extracellular signal-regulated kinase (ERK) activity. When RUNX1::RUNX1T1-deficient, WT1 can activate the mitogen-activated extracellular signal-regulated kinase/ERK axis but not through targeting DUSP6. These results provide a mechanism by which WT1 together with RUNX1::RUNX1T1 suppresses cell proliferation through WT1/DUSP6/ERK axis in AML. The current study provides an explanation for the controversial prognostic significance of WT1 expression in AML patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Xu N, Dao FT, Shi ZY, et al. WT1 together with RUNX1::RUNX1T1 targets DUSP6 to dampen ERK activity in acute myeloid leukaemia. Br J Haematol. 2024. PMID: 39191510. doi:10.1111/bjh.19721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。